PHILADELPHIA, Aug. 25, 2026 (GLOBE NEWSWIRE) —
ARS Pharmaceuticals, Inc.
(NASDAQ: SPRY):
Grabar Law Office is investigating claims on behalf of shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY).
What is The Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased
ARS Pharmaceuticals,
Inc.
(NASDAQ: SPRY)
shares prior to
March 9, 2026
,
and still hold shares today,
you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. Please visit
https://grabarlaw.com/the-latest/ars-shareholder-investigation/
, contact Joshua Grabar at
[email protected]
,
or call 267-507-6085 to learn more.
What is Alleged? It is alleged in a recently filed federal securities fraud class action complaint that ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) certain corporate officers knew or recklessly disregarded potential timeline issues with CVS Caremark’s formulary addition and coverage decision related to neffy; (ii) the guidance ARS Pharmaceuticals provided to investors related to the timeline for expansion of insurance coverage for neffy with CVS Caremark may be significantly shifted, impacting commercialization efforts; and (iii) the expanded insurance coverage may not be available by the July 1 deadline, thus, ARS Pharmaceuticals would not have the expanded insurance coverage for neffy with CVS Caremark for the summer and back-to-school seasons.
On June 24, 2026, after the market closed, ARS Pharmaceuticals published a press release announcing that ARS Pharmaceuticals did not receive expanded insurance coverage for neffy through CVS Caremark by the guided July 1, 2026 deadline, which meant that ARS Pharmaceuticals did not have expanded insurance coverage for neffy for the summer or back-to-school allergy seasons. ARS Pharmaceuticals allegedly also stated that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027. On this news, the price of ARS Pharmaceuticals stock declined nearly 24%, according to the complaint.
What Can You Do Now?
If you purchased
ARS Pharmaceuticals,
Inc.
(NASDAQ: SPRY)
shares prior to
March 9, 2026
,
and still hold shares today,
please visit
https://grabarlaw.com/the-latest/ars-shareholder-investigation/
, contact Joshua Grabar at
[email protected]
,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. #SPRY $SPRY #ARSPharmaceuticals
Hub Group, Inc. (NASDAQ: HUBG):
Grabar Law Office is investigating claims on behalf of shareholders of Hub Group, Inc. (NASDAQ: HUBG).
What Is This Investigation About? The investigation concerns whether certain officers and directors of Hub Group, Inc. breached the fiduciary duties they owed to the company.
If you purchased
Hub Group, Inc. (NASDAQ: HUBG)
,
shares prior to April 28, 2023
,
and still hold shares today,
you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.
Please
visit
https://grabarlaw.com/the-latest/hubg-shareholder-investigation/
, contact Joshua Grabar at
[email protected]
,
or call 267-507-6085.
What is Alleged? As alleged in a recently filed securities fraud class action complaint, Hub Group, Inc. (NASDAQ: HUBG), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Hub Group’s financial statements prepared for the periods from Q1 2023 to Q4 2024, including annual reports for 2023 and 2024, contained material misstatements caused by the premature and incorrect recognition of certain transactions concerning, among other things, Hub Group’s operating revenue, operating income, revenue recognition, effectiveness of internal controls and procedures, and drivers of financial results and growth; and (2) Hub Group’s financial statements prepared for the periods from Q1 2025 to Q3 2025 contained material misstatements caused by the understatement of purchased transportation costs and accounts payable concerning, among other things, Hub Group’s operating expenses, purchased transportation and warehousing expenses, operating income, effectiveness of internal disclosure controls and procedures, and drivers of financial results and growth.
What Can You Do Now?
If you purchased
Hub Group, Inc. (NASDAQ: HUBG)
,
shares prior to April 28, 2023
,
and still hold shares today,
you are encouraged to visit
https://grabarlaw.com/the-latest/hubg-shareholder-investigation/
, contact Joshua Grabar at
[email protected]
,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #HUBG #HubGroup #HUBG
Insulet Corporation (NASDAQ: PODD):
Grabar Law Office is investigating claims on behalf of shareholders of Insulet Corporation (NASDAQ: PODD).
What Is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased
Insulet Corporation (NASDAQ: PODD)
shares prior to February 21, 2025
,
and still hold shares today,
you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.
Please visit
https://grabarlaw.com/the-latest/insulet-shareholder-investigation/
, contact Joshua Grabar at
[email protected]
,
or call 267-507-6085.
What Is Alleged? As alleged in a recently filed federal securities fraud class action complaint, Insulet Corporation (NASDAQ: PODD), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failed to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
The truth began to emerge on March 12, 2026, when Insulet disclosed that it had “initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring.” Then, on May 26, 2026, Insulet disclosed the “initat[ion]” of another “voluntary Medical Device Correction” (the “May 2026 MDC”), this time “for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery.”
What Can You Do Now?
If you purchased
Insulet Corporation (NASDAQ: PODD)
shares prior to February 21, 2025
,
and still hold shares today,
you are encouraged to visit
https://grabarlaw.com/the-latest/insulet-shareholder-investigation/
, contact Joshua Grabar at
[email protected]
,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #Insulet, #PODD $PODD
Roblox Corporation
(NYSE: RBLX):
Grabar Law Office is investigating claims on behalf of shareholders of Roblox Corporation (NYSE: RBLX).
What is The Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased
Roblox Corporation (NYSE: RBLX)
,
shares prior to
October 31, 2024,
and still hold shares today,
you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit
https://grabarlaw.com/the-latest/roblox-shareholder-investigation/
,
contact Joshua Grabar at
[email protected]
,
or call 267-507-6085.
What is Alleged? A recently filed securities fraud class action complaint alleges that Roblox Corporation (NYSE: RBLX) via certain of its officers, made material misrepresentations to investors concerning Roblox’s anticipated earnings growth. Specifically, Roblox stated that 2026 bookings would grow by 22% to 26%, which reflected Roblox’s “confidence in the adoption of our age-checking technology.” Roblox also stated that its age verification features provided “a bigger growth opportunity in the 18-plus demographic than previously assumed” and stated that its “18 and over cohort is growing at over 50%[.]” In truth, as alleged, Roblox’s age verification rollout was causing a slowdown in on-platform communication, app store rating reductions, and a considerable reduction in organic growth.
What Can You Do Now?
If you purchased
Roblox Corporation (NYSE: RBLX)
shares prior to
October 31, 2024,
and still hold shares today,
you are encouraged to visit
https://grabarlaw.com/the-latest/roblox-shareholder-investigation/
,
contact Joshua Grabar at
[email protected]
,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #Roblox #RBLX $RBLX
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: [email protected]
